Key Points
- CEO Zhenya Lindgardt sold 20,139 shares of Sera Prognostics at an average price of $2.00, totaling $40,278. The sale covered tax-withholding obligations tied to vested equity awards, reducing her ownership by 2.33% to 844,870 shares.
- SERA shares opened at $2.00, with a 52-week range of $1.56 to $3.95 and a market capitalization of approximately $78.9 million. The company recently reported a quarterly loss of $0.18 per share, below the $0.15 analyst consensus, and revenue of $30,000 versus $70,000 expected.
- Analyst sentiment remains mixed but averages to a “Moderate Buy”, with a consensus price target of $5.50 compared with the $2.00 share price. Institutional investors own approximately 54.64% of the company.
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total value of $40,278.00. Following the completion of the transaction, the chief executive officer owned 844,870 shares of the company's stock, valued at approximately $1,689,740. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Sera Prognostics Stock Performance
Shares of SERA opened at $2.00 on Thursday. Sera Prognostics, Inc. has a 52-week low of $1.56 and a 52-week high of $3.95. The stock's 50-day simple moving average is $2.05 and its 200 day simple moving average is $2.02. The stock has a market capitalization of $78.90 million, a price-to-earnings ratio of -2.99 and a beta of 0.98.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.07 million. On average, research analysts forecast that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently weighed in on SERA. Craig Hallum began coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They set a "buy" rating and a $6.00 target price on the stock. Weiss Ratings lowered shares of Sera Prognostics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sera Prognostics has an average rating of "Moderate Buy" and an average price target of $5.50.
Read Our Latest Analysis on SERA
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of SERA. Squarepoint Ops LLC increased its position in shares of Sera Prognostics by 8.9% in the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company's stock worth $285,000 after purchasing an additional 7,643 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in Sera Prognostics during the first quarter valued at approximately $25,000. Citadel Advisors LLC lifted its position in Sera Prognostics by 1.9% during the third quarter. Citadel Advisors LLC now owns 653,746 shares of the company's stock valued at $2,000,000 after purchasing an additional 12,439 shares during the last quarter. Lido Advisors LLC purchased a new position in Sera Prognostics in the 3rd quarter worth approximately $68,000. Finally, Cetera Investment Advisers bought a new position in shares of Sera Prognostics in the 4th quarter worth $74,000. Hedge funds and other institutional investors own 54.64% of the company's stock.
Sera Prognostics Company Profile
(
Get Free Report)
Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.
Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
